Nanoviricides, Inc. NNVC
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Nanoviricides, Inc. (NNVC) is a healthcare company listed in the US with a market value of about $31M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -62%.
About Nanoviricides
Nanoviricides is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 74% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — |
| Net income | -$8M | -$9M | -$8M | -$9M | -$8M | -$9M | -$13M | -$8M | -$9M | -$10M |
| Free cash flow | -$8M | -$9M | -$6M | -$6M | -$6M | -$8M | -$7M | -$7M | -$8M | -$8M |
| EPS (diluted) | $-0.41 | $-0.63 | $-0.70 | $-0.74 | $-0.70 | $-0.81 | $-2.39 | $-2.35 | $-2.60 | $-3.40 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -75.6% | -100.8% | -58.7% | -47.5% | -27.8% | -23.1% | -36.8% | -81.7% | -52.8% | -47.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Nanoviricides pay a dividend?
Not currently.
Is Nanoviricides a good stock to buy?
We do not give buy or sell advice. Nanoviricides scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.